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Abstract 
Introduction: Non-alcoholic steatohepatitis (NASH) is a chronic liver disease that can 
progress to cirrhosis and hepatocellular carcinoma. Diagnosis of NASH requires liver 
biopsy and is defined as presence of hepatic steatosis and inflammation with or 
without fibrosis. Although NASH is the most common cause of liver disease in the 
west world and among the top three indications for liver transplantation, there are no 
universally accepted pharmacological therapies and advances have been slow.  
Areas covered: Current evidence about lifestyle interventions, bariatric surgery and 
pharmacotherapy is reviewed. Dietary recommendations and lifestyle interventions 
have shown promising results but are difficult to maintain. At the moment, there is no 
universally approved medical treatment for NASH. Pioglitazone and vitamin E are 
recommended by guidelines in selected patients. An increasing number of phase II 
and III trials in non-cirrhotic NASH are currently recruiting and their preliminary 
results discussed. 
Expert commentary: As NASH is classified as a medical condition of an unmet 
therapeutic need, it has gained an accelerated access pathway for drug approval based 
on surrogate endpoints. It is therefore expected that within the next five years, there 
will be at least one approved agent for the pharmacological treatment of pre-cirrhotic 
NASH. 
 
Keywords: fibrosis, obeticholic acid, elafibranor, fatty liver, cirrhosis, bariatric 
surgery 
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1.0 Introduction  
Non-alcoholic fatty liver disease (NAFLD) is defined as the presence of 
hepatic steatosis in patients who do not consume excessive alcohol and who do not 
have other secondary causes of steatosis such as steatogenic medication [1, 2, 3]. It is 
considered the hepatic manifestation of the metabolic syndrome and is associated with 
type II diabetes, obesity and dyslipidaemia [4, 5, 6]. The prevalence of obesity and 
metabolic syndrome have increased exponentially over the recent years hence 
contributing to the rising prevalence of NAFLD [7]. NAFLD is projected to become 
the main indication for liver transplantation in the next 10 years [2, 3, 8]. Based on the 
histological features, NAFLD is differentiated in simple steatosis (NAFL) and non-
alcoholic steatohepatitis (NASH) [2, 3], which is characterized by lobular 
inflammation, ballooning and higher risk of progression to cirrhosis [9]. Although 
there is rigorous scientific interest in approaching novel therapeutic pathways to treat 
NASH, the gold standard remains lifestyle modification with a combination of weight 
loss and exercise [10, 11]. During the last decades, a variety of different agents, which 
target specific pathophysiologic mechanisms, have been studied in controlled trials in 
the treatment of NASH. A better understanding of NAFLD pathogenesis will not only 
help clarify how the disease progresses but may also result in the discovery of new 
treatment strategies.  Potential therapeutic targets and approaches include the use of 
insulin sensitizers, antioxidants/anti-inflammatory and anti-fibrotic agents. This 
review focuses on therapeutic approaches that have already been tested in patients 
with NASH, with a brief mention on promising future agents that are already at least 
in phase II trials. 
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2.0 Management principles 
 NAFL is considered a benign condition and is not associated with increased 
liver-related morbidity hence no liver-specific treatment is required. The presence of 
coexisting conditions like diabetes mellitus, dyslipidaemia and obesity should be 
investigated and managed [2, 3]. Conversely, patients with NASH might potentially 
progress to cirrhosis and treatment is necessary. Patients with NASH have increased 
risk of death from liver-related and cardiovascular causes [12].  
2.1 Diet and lifestyle modification / exercise  
 NAFLD and NASH are strongly associated with the metabolic syndrome and 
the majority of patients are overweight or obese, with co-morbidities like diabetes 
mellitus or insulin resistance and hyperlipidemia. Hence the cornerstone of treatment 
is a combination of weight reduction and exercise through a combination of diet, 
physical activity and general lifestyle changes [13]. Behavioural change through diet 
and exercise may not suffice alone as other parameters are still under investigation, 
such as smoking, which is associated with increased insulin resistance and possibly 
with advanced liver fibrosis [14, 15].  
 From as early as 1970, studies indicated that weight loss is associated with 
improvement in liver histology as evidenced by follow up biopsies [16] and liver 
enzyme levels [17]. Small studies verified that weight reduction is correlated with 
lower levels of aminotransferases and showed that liver biochemistry was aggravated 
when patients regained weight [18]. The prevalence of metabolic syndrome in obese 
patients was also reduced when weight loss was achieved by diet and medical 
treatment [19]. Patients who accomplish a reduction of more than 5% of their body 
weight have improved insulin sensitivity and steatosis. Furthermore, when patients 
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lose more than 9% of body weight, ballooning, inflammation and nonalcoholic fatty 
liver disease score (NAS) are also improved [20].  
 A randomized controlled trial (RCT) with 31 patients tested the efficacy of 
intense dietary and lifestyle interventions with exercise compared with general 
education for 48 weeks. The lifestyle interventions arm achieved an average of 9.3% 
reduction of body weight versus 0.2% in the other group, which was also associated 
with a beneficial effect in liver histology since liver steatosis was improved. Overall a 
weight loss of more than 7% of body weight was linked to significant improvement in 
steatosis, lobular inflammation, ballooning and NAS, but not fibrosis. Whether liver 
fibrosis may not be affected as much from weight loss or whether a longer treatment 
period is needed, is unclear [11]. However a recent retrospective study of 45 patients 
showed regression of fibrosis when patients lost more than 10% of body weight 
regardless of the method used (bariatric therapy, diet, medical therapy for weight 
loss). In addition when patients regained weight, fibrosis worsened [21].  
 The largest clinical study thus far, assessed 293 individuals with biopsy 
proven NASH for one year. Patients received dietary advice, motivation to exercise 
and were instructed to log their daily caloric consumption and activities. Assessment 
of follow up biopsies recorded a 25% resolution of NASH and a 47% of NAS 
improvement. Improvement in portal inflammation and fibrosis was greater in 
patients with weight loss more than 10% of body weight. In total 19% of patients 
achieved regression of fibrosis after a year. It is noteworthy that from those patients 
who reached 10% of weight loss, 45% showed regression of fibrosis thus underlining 
the importance of weight reduction as well as the dose-response relationship between 
weight loss and hepatic histology improvement. On the other hand the majority of 
patients with deteriorating liver histology had minimal or no weight loss. In total, less 
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than 50% of patients lost more than 7% of body weight and 25% achieved resolution 
of NASH questioning the efficacy of these interventions in real life where usually 
success rates are lower [22].  
 Published studies highlight the association between diet and exercise with 
improvement in the biochemical levels and histological findings of NAFLD patients 
[23]. Further supporting the role of dietary intervention, small studies displayed 
histological improvement though without statistical significance [24]. The focus of 
current research is to characterize unhealthy dietary habits for NAFLD patients. In 
this setting, a prospective study showed that NAFLD patients tend to consume more 
soft drinks and meat and less omega-3 fatty acids [25]. Similarly fructose 
consumption is increased in NAFLD patients and is associated with increased fibrosis 
[26]. Interestingly, diets with either restriction of fat or carbohydrate result in weight 
reduction [27] while the Mediterranean diet seems to improve liver steatosis and 
insulin sensitivity even without weight loss, albeit in a small group of patients [28].  
 Exercise, along with diet, is a key part of behavioral changes with both 
beneficial effects in cardiovascular risk factors and leading to body weight reduction 
[29]. Despite the fact that physical activity plays an important role in NAFLD 
management, the majority of patients do not exercise and fitness is inversely 
associated with the prevalence of NAFLD [30]. Indeed even when weight loss is not 
accomplished through exercise there are beneficial results from physical activity. A 
placebo controlled RCT of 19 sedentary obese patients assessed hepatic function by 
magnetic resonance imaging and blood testing after 4 weeks of aerobic training or 
placebo (stretching), documenting a reduction in hepatic triglyceride concentration 
[31]. In a similar study, resistance exercise decreased fat concentration in the liver, as 
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measured by magnetic resonance, and ameliorated insulin resistance, glucose control 
and lipid oxidation, despite the fact that once again weight loss was not achieved [32].  
 Data from a recent meta-analysis suggests that exercise has a beneficial role in 
reducing intrahepatic lipids but not in the improvement of liver biochemistry even 
when weight reduction is minimal or none. The vast heterogeneity and small number 
of studies included in the analyses indicates that more research regarding exercise 
interventions is required in order to accurately assess its role in NAFLD treatment 
[33].  Furthermore the same researchers concluded that changes in the intensity or 
amount of aerobic exercise do not have a significant effect on liver fat reduction and 
fail to improve weight loss [34]. Despite this finding, a significant difference between 
all exercise groups and placebo was documented in regards to intrahepatic lipid and 
visceral adipose tissue, as measured by magnetic resonance [34].  
2.2 Orlistat 
 Weight reduction through diet and lifestyle modification is advocated as the 
first line of intervention in NASH but the majority of real life patients are unable to 
comply with dietary modifications. Orlistat, an oral inhibitor of gastric and pancreatic 
lipases, was introduced in obese patients with NASH in order to assist with weight 
loss. Initially a case series of 3 patients showed marked improvement in histological 
and biochemical markers after 6 or 12 months of orlistat treatment [35]. In a RCT of 
52 patients, orlistat in conjunction with a weight loss program reduced ALT levels 
and steatosis by ultrasound after 6 months. Interestingly, there was no significant 
difference in weight reduction between orlistat and placebo group [36]. Another RCT 
with fifty overweight patients demonstrated that the reduction of aminotransferases 
and body weight were similar when comparing treatment with vitamin E plus diet or 
Page 7 of 49
URL: https://mc.manuscriptcentral.com/erh   Email: Anna.Woolman@informa.com
Expert Review of Gastroenterology & Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
vitamin E plus diet and orlistat. In addition, no improvement in liver histology was 
documented after 9 months of treatment regarding hepatic steatosis, ballooning, 
inflammation or fibrosis [20].  
2.3 Bariatric surgery 
Bariatric surgery is indicated in severely or morbidly obese patients and a 
variety of procedures have been performed. These procedures include bilio-intestinal 
bypass, gastric band, laparoscopic adjustable gastric banding, Roux-en-Y gastric 
bypass and sleeve gastrectomy. Jejuno-ileal bypass was abandoned because of liver 
complications that developed after surgery ranging from increased fatty infiltration to 
cirrhosis and liver failure [37]. The majority of patients undergoing bariatric 
procedures also have NAFLD. A recent Cochrane review found insufficient data from 
RCTs and quasi-randomised clinical studies in order to consider bariatric surgery as a 
therapeutic resource in patients with NASH [38]. Although recommendations have 
not yet established bariatric procedures as an eligible treatment for NAFLD and 
NASH, weight loss is known to increase insulin sensitivity and also act beneficially to 
visceral fat loss [39].  
In a small study, laparoscopic adjustable gastric band placement was 
associated with sustained weigh loss and improved liver biochemistry and insulin 
sensitivity. Follow up biopsies indicated that steatosis, inflammation, ballooning and 
fibrosis also reduced, although a lot of patients had to undergo revision surgery [40]. 
A prospective study from France evaluated the presence of fibrosis and non-alcoholic 
steatohepatitis in 381 obese patients after bariatric surgery. They concluded that the 
majority of patients had decreased steatosis and ballooning after one and five years, 
albeit inflammation remained unchanged compared with baseline measurements.  The 
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most significant improvement was observed the first year after the procedure and was 
sustained. Interestingly, there was a statistically significant increase in fibrosis but 
with low fibrosis score of F1 or less at 5 years [41]. Conversely a recent study 
presented evidence of improvement of fibrosis along with the histological features of 
NAFLD in liver biopsies after bariatric surgery [42]. Intriguingly, steatosis and 
inflammation resolved in 75% and fibrosis of any grade improved in half of the 160 
patients, although the second liver biopsy was done in different time intervals and was 
not always accompanied with biochemical liver markers. The team from Lille 
published a new study that included 109 obese patients, over the last twenty years, 
who had a follow up liver biopsy one year after bariatric surgery. Body mass index, 
insulin resistance index and other markers were significant improved and NASH 
disappeared from 85% of the patients [43]. Bariatric surgery induced histological 
improvement of NASH and fibrosis amelioration. The persistence of NASH was 
correlated with less weight loss and refractory insulin resistance.  
In conclusion, foregut bariatric surgery is not yet an established treatment of 
NASH and more RCTs are awaited. However, it is frequently practiced in overweight 
non-cirrhotic NAFLD patients with encouraging results.    
2.4.0 Insulin sensitizing agents  
There is a well-documented association between non-alcoholic steatohepatitis 
and the metabolic syndrome. This association has led to a rigorous investigation of the 
majority of type 2 diabetes regimens for the treatment of NAFLD and NASH. 
2.4.1 Metformin 
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One of the first anti-diabetic agents assessed in NASH was metformin. A comparison 
between metformin, vitamin E and diet alone exhibited the benefit of metformin in an 
open label, randomized trial with 110 patients, by improving aminotransferases levels 
and decreasing liver fat and necroinflammation in a limited number of 17 patients 
[44]. Besides liver function tests improvement, metformin facilitated weight loss and 
had a beneficial role in necroinflammation and fibrosis in a small number of patients 
as shown in the follow up biopsy. However more recent trials have not confirmed 
these results, as metformin did not to have a significant effect neither on liver 
histology nor on liver biochemical results [45]. In a double blind, placebo-controlled 
RCT with 173 patients, metformin did not significantly improve liver biochemistry or 
histology in children and adolescents with NAFLD and NASH [46]. Furthermore, 
metformin provided no additional benefit when combined with another anti-diabetic 
agent such as rosiglitazone [47]. Although metformin does not improve NASH, there 
is evidence that it might reduce the incidence of hepatocellular carcinoma. In a recent 
nationwide case control study from Taiwan with 97,430 HCC patients and 194,960 
matched controls, the use of metformin was associated with a decreased risk of HCC 
in a dose dependent manner, as HCC risk was reduced by 7% for each incremental 
year of metformin use [48].  
2.4.2 Thiazolidinediones 
 Pioglitazone and rosiglitazone are agonists of the nuclear peroxisome 
proliferator activated receptor-gamma (PPARγ), thus acting by improving insulin 
sensitivity. The effect of rosiglitazone and pioglitazone on liver biochemistry and 
histology (steatosis, ballooning, inflammation and fibrosis) has been vigorously 
investigated in NASH both in diabetic and non-diabetic patients.  
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In 2008, the FLIRT RCT tested the effect of rosiglitazone in 63 patients with 
biopsy-proven NASH for one year. Steatosis and transaminase levels improved after 
treatment, although fibrosis and other histology scores remained unchanged. There 
was a documented increase in weight in the rosiglitazone group due to peripheral 
oedema [49]. The study showed a rapid reduction in liver biochemistry in the first 
months of treatment and a gradual return to baseline levels after the end of the 
treatment period. An extension of this trial was designed aiming to assess further 
histological improvement with longer treatment. Unfortunately the goal of fibrosis 
regression was not achieved and no additional benefit was documented after 2 years 
of treatment [50]. Researchers attempted to combine rosiglitazone with other agents 
like metformin and losartan however the results were not as promising [47]. 
Moreover, rosiglitazone has been associated with an increased risk of myocardial 
infarction and heart failure and as a result is no more accessible in Europe [51, 52].  
In a pilot study of 18 non-diabetic patients with NASH treated with 
pioglitazone for 48 weeks, liver biochemistry and histology significantly improved 
[53]. This improvement may be modulated by an adiponectin-mediated effect on 
insulin sensitivity and hepatic fatty acid metabolism rather than by changes in pro-
inflammatory cytokines [54]. In a RCT of pioglitazone and dietary restriction versus 
diet restriction alone in 55 patients with NASH, pioglitazone significantly improved 
all histological measures apart from fibrosis [55]. Interestingly discontinuation of 
pioglitazone treatment reverses the beneficial effects on aminotransferase levels and 
inflammation markers [54]. In a UK RCT of 74 patients, pioglitazone treatment for 12 
months resulted in significant weight gain and improvements in metabolic and 
histological parameter, including liver fibrosis [56].  
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The PIVENS trial was the largest RCT to assess the use of pioglitazone in 
biopsy proven NASH compared with vitamin E or placebo therapy. 247 non-diabetic 
patients were randomized in three groups and received vitamin E, pioglitazone or 
placebo for 96 weeks with additional lifestyle and dietary recommendations. 
Pioglitazone was associated with significant reductions in hepatic steatosis, lobular 
inflammation and resolution of steatohepatitis as compared with placebo although no 
improvement in fibrosis was seen. The study concluded that there was no benefit of 
pioglitazone over placebo since the drug failed to meet the pre-specified level of 
significance for the improvement in histologic findings [57].  
There are adverse effects of pioglitazone that need to be acknowledged. 
Congestive heart failure increases with pioglitazone, nevertheless without an 
associated increase in cardiovascular mortality [58, 59]. Furthermore, pioglitazone 
presents the same side effect profile with the other thiazolidinediones regarding 
weight gain, bone loss and pedal edema [60].  
Pioglitazone is included in the AASLD and EASL management 
recommendations for patients with biopsy proven NASH although the optimal 
duration of treatment is yet to be determined [2, 3]. However the long-term efficacy is 
debatable and the experience with rosiglitazone suggests no additional benefit with 
longer therapy schemes [50]. Moreover both biochemical and histological 
improvement return to baseline after treatment discontinuation while weight gain is 
not easily reversible [54].  
2.4.3 Liraglutide 
 Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue with longer 
duration and was introduced for the treatment of diabetes mellitus in obese patients in 
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2009 [61]. Liraglutide improves glycaemic control and promotes weight loss [62], 
with only minor adverse events initially documented. Liraglutide and other GLP-1 
analogues have two advantages. Firstly, they have been used for a number of years 
already in other diseases and thus the safety profile in known. Secondly, they improve 
to a large extent the metabolic syndrome parameters that are implicated in NASH, 
hence making them attractive therapeutic options. Liraglutide was recently 
investigated in 52 patients in a phase II double blind RCT in patients with NASH, 
with the primary outcome being resolution of NASH and no deterioration of fibrosis  
[63]. The results were promising and showed that 39% (9/23) of patients in the 
liraglutide group had resolution of the histological features of NASH compared to 9% 
(2/22) of patients in the placebo arm. In addition, patients in the liraglutide arm had 
significantly reduced weight and BMI at the end of treatment compared with those 
that received placebo.  
2.4.4. Sitagliptin 
Sitagliptin, a dipeptidyl peptidase 4 (DDP-4 inhibitor) is another anti 
hyperglycemic agent studied in animal models with hopeful results [64]. An open 
label observational pilot study with 15 NASH patients with diabetes assessed the 
effect of sitagliptin for one year. Paired liver biopsies revealed a significant decrease 
in ballooning and histological activity scores [65]. However, when further trials 
evaluated sitagliptin on patients with NASH, one study was terminated early 
(NCT01260246) and another was withdrawn prior to enrollment (NCT02263677). In 
a recent RCT of sitagliptin for 24 weeks in 50 NAFLD patients, there was no 
significant reduction in liver fat as measured by MRI in comparison with the placebo 
group [66].   
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2.5 Statins and ezetimibe 
One of the main therapies for dyslipidaemia are statins, hence the efficacy of this 
agents has also been assessed in the treatment of NASH but without robust results. 
The use of statins is indicated in patients with NASH and dyslipidaemia in order to 
reduce cardiovascular risk, however there is no strong evidence yet to prove that they 
can improve or delay liver disease progression. A prospective randomised open label 
study from Greece with 1600 patients, demonstrated a significant improvement of 
liver enzymes in patients receiving atorvastatin albeit no liver histology was assessed 
with biopsy after treatment [67]. Patients underwent liver biopsy after a year of statin 
therapy in small studies from USA and Japan, though with conflicting results. 
Simvastatin appeared to have no effect on the histopathological signs of NASH [68], 
however pravastatin leads to improvement of the biochemical markers and even 
histology in some patients [69]. Nevertheless, progression of fibrosis was evident is 
some patients. Recently a prospective open label uncontrolled study with 20 NASH 
patients reported resolution of NASH after 12 months of monotherapy with 
rosuvastatin (10 mg/d). All patients underwent liver biopsy before and after treatment 
and although body weight and waist circumference remained unchanged, 19 patients 
had histological resolution of NASH [70]. Furthermore statin use was associated with 
a reduction in incident of hepatocellular carcinoma among patients with diabetes and 
HCV in large cohorts of patients [71, 72].  
 A recent double blind, placebo-controlled RCT with 50 biopsy proven NASH 
patients examined the efficacy of ezetimibe (10mg/d) for 24 weeks mainly by 
assessing liver fat change as measured by magnetic resonance imaging and was 
negative [73].   
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2.6 Polyunsaturated fatty acids (PUFAs) – Omega-3 fatty acids  
 In both animal and human intervention trials it was suggested that 
polyunsaturated fatty acids (PUFA) had an impact on both lipid metabolism and 
insulin sensitivity through multiple pathways. Thus it has been hypothesized that 
PUFA supplementation, which cannot be synthesized by mammals, can have 
beneficial effect on NAFLD [74]. Administration of eicosapentaenoic acid and 
docosahexaenoic acid for 48 weeks showed no positive effect over placebo on both 
histological markers and insulin resistance or lipid control [75]. In a phase 2 RCT in 
243 patients with biopsy proven NASH, two dosages of ethyl-eicosapentaenoic acid 
were tested and no histological improvement was demonstrated after one year of 
treatment, whilst the effect on serum triglycerides appeared moderate [76]. A possible 
explanation for those negative results is the lack of an optimal dosage of 
polyunsaturated fatty acids hence higher dosages should be used and standardised 
according to their lipid lowering effect.  
2.7 Ursodeoxycholic acid (UDCA) 
UDCA, a bile acid, was thought to be a promising treatment for NASH based 
on small pilot studies with the potential to improve liver biochemistry and histology. 
In the first large RCT including 166 patients, no significant difference between the 
UDCA (13-15 mg/Kgr/day) and placebo was identified in biochemistry or histology 
[77]. The result was partially attributed to low dosage and a higher dosage of UDCA 
(23-28 mg/Kgr/day) was tried in a further RCT that included 185 patients for 18 
months [78]. Nonetheless, the result remained the same and no liver histology 
improvement was documented regardless of the histological score used. Hence the 
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EASL and AASLD guidelines do not recommend the use of UDCA in NAFLD or 
NASH patients [2, 3].  
2.8 Vitamin E 
The hypothesis that an antioxidant agent such as vitamin E (a-tocopherol) can 
ameliorate liver histology has been frequently tested in NASH patients. Vitamin E 
improved histological findings in a small double-blind RCT of 49 patients and a 
prospective open label study of 23 patients after 6 and 12 months of treatment 
respectively [79, 80]. In those studies the number of patients was small and the dosage 
and formulation of vitamin E was variable. A combination with pioglitazone  was 
initially tested in a small randomized prospective trial with 20 NASH patients with 
positive results [81]. Lately the PIVENS and TONIC studies assessed the efficacy of 
vitamin E in large numbers of patients with biopsy confirmed NASH in adult and 
paediatric populations respectively. The PIVENS study compared pioglitazone with 
vitamin E and placebo for 96 weeks and demonstrated the superiority of vitamin E 
over placebo in the improvement of liver histology [57]. When compared to placebo, 
vitamin E treatment demonstrated a higher percentage of NAS score improvement 
(43% vs. 19%) and liver biochemistry improvement [57]. In the children and 
adolescents cohort, although vitamin E was not superior to placebo in ALT reduction, 
it resulted in significantly higher resolution of NASH [46]. Both PIVENS and TONIC 
used 800IU/day of vitamin E for duration of 96 weeks but neither presented sufficient 
evidence of regression of fibrosis. When vitamin E was used as the control treatment 
in a study that combined metformin and bicyclol, the histological features of steatosis, 
inflammation and ballooning were decreased in both groups [82]. On account of those 
results, EASL and AASLD guidelines consider vitamin E as a potential short term 
treatment for non-diabetic NASH patients [2, 3] despite a potential increase in all-
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cause mortality, haemorrhagic stroke and prostate cancer that has been documented 
[83, 84, 85].  
2.9 Obeticholic acid (6α-ethyl-chenodeoxycholic acid) 
A very promising agent that has emerged from animal and human studies is 
obeticholic acid, a bile acid derivative that acts as an agonist of the farnesoid X 
receptor (FXR). Bile acids might interfere in the metabolic pathways of glucose and 
lipids through the FXR [86]. In a small RCT of 64 diabetic patients with NASH, 
obeticholic acid administered for 6 weeks increased insulin sensitivity and reduced 
liver biochemical markers compared to placebo in the expense of a rise in LDL levels 
[87]. A large, multicentre RCT of obeticholic acid versus placebo for 72 weeks was 
subsequently performed in 283 patients with biopsy proven NASH [88]. The 
obeticholic acid group showed improved liver histology compared with placebo, 
including fibrosis, ballooning, steatosis and inflammation. Furthermore obeticholic 
acid was associated with weight loss. The most common adverse event were the 
presence of pruritus, elevated LDL and reduced HDL cholesterol levels in the 
obeticholic acid group that reversed after treatment [88]. Albeit the presence of 
pruritus and the rise of total and LDL cholesterol, obeticholic acid appears to be a 
promising agent for the treatment of NASH, once long term safety is assured and is 
currently tested in a phase III trial (NCT02548351).  
2.9 Elafibranor 
Elafibranor (formerly known as GFT505) is a dual peroxisome proliferator-
activated receptor alpha/delta agonist (PPARα/δ agonist), which provided some 
hopeful results in patients with metabolic syndrome and obesity [89, 90]. Human liver 
PPARα gene expression negatively correlates with NASH severity, while histological 
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improvement is associated with an increase in expression of PPARα and its target 
genes [91]. In animal models of NAFLD/NASH, elafibranor improved liver histology 
by both PPAR-a dependent and -independent mechanisms [92]. Subsequently 
elafibranor was introduced in a double blind placebo controlled RCT with 276 non-
cirrhotic NASH patients in two doses of 80mg and 120mg daily for 52 weeks in order 
to define histological response. The primary outcome of reversal of NASH without 
worsening of fibrosis was not achieved in the elafibranor arms compared with 
placebo. Nevertheless, when a post hoc analysis assessed the response using a 
modified definition of NASH resolution, the 120mg arm exhibited a significant 
improvement. Furthermore liver biochemistry, glucose and lipids profiles were 
reduced as well, without weight gain [93]. An ongoing phase III trial will further 
evaluate the efficacy and long term safety of elafibranor versus placebo in NASH 
patients (NCT02704403).  
3.0 The future  
 Future research for effective pharmacotherapy treatment in NAFLD and 
NASH is challenging. A lot of agents are being investigated and some emerging data 
from rodent trials are promising. As NASH pathogenesis and progression are 
illuminated, more potential therapeutic targets emerge [94]. Novel drugs aim at 
multiple targets and pathways, such as inflammation and oxidative stress, the gut liver 
axis, the metabolic factor and progression of fibrosis [95].  
Aramchol, a fatty acid-bile conjugate is a potential therapeutic agent which 
seems to reduce liver fat as assessed by magnetic resonance spectroscopy [96]. An 
ongoing trial is recruiting patients to evaluate the efficacy and safety of two aramchol 
doses versus placebo in NASH patients (NCT02279524). Volixibat (SHP-626), is an 
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apical sodium dependent bile acid transporter inhibitor (ASBTi) and is being 
evaluated in an ongoing phase 2 RTC for 48 weeks. The primary outcome measures 
the effect of volixibat on liver histology (NCT02787304). 
Saroglitazar is a dual PPAR agonist that has demonstrated significant 
improvement in glycemic and lipid control in diabetic patients and appears to 
ameliorate aminotransferases in 31 NAFLD patients after 24 weeks [97]. A series of 
trials from India are evaluating potential benefits from this agent [98]. A RCT 
evaluated a pradigastat, which is a diacylglycerol acyltransferase-1 inhibitor, in 52 
NAFLD patients for 24 weeks with two different doses. Pradigastat improved liver fat 
after 12 and 24 weeks when administered at the high dose (10/20 mg/day) [99].   
 An inhibitor of phosphodiesterase-4 (ASP9831) with promising results from a 
phase 1 trial was evaluated in 93 patients with NASH compared with placebo but no 
significant change was observed in liver biochemistry after 12 weeks of 
administration at either of the two investigated doses [100]. In murine models of 
NASH, a pan-caspase inhibitor, emricasan (IDN-6556) reduced hepatocyte apoptosis 
and consequently attenuated liver injury and fibrosis [101].  Emricasan significantly 
reduced transaminases after 28 days in 38 patients with NAFLD [102]. A larger RCT  
is currently recruiting participants (NCT02686762).  
Cenicriviroc, a dual CCR2/CCR5 antagonist is evaluated in a phase 2b 
randomized, double blind, placebo controlled study with 289 NASH patients for a 
period of 2 years [103].  
GS-6624 (simtuzumab) is a monoclonal antibody against lysyl oxidase-like 2 
(LOXL2) and GS-4497 is a molecule that inhibits apoptosis signal-regulating kinase 1 
(ASK1) which acts as a mediator of oxidative stress. Both these agents are being 
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tested in at least three ongoing clinical trials to assess the efficacy of simtuzumab 
alone or in combination with GS-4997 in patients with NASH with and without 
cirrhosis. (NCT02466516, NCT01672866, NCT01672879). Finally anti-CD3 
antibodies that reduce insulin resistance in animals were included in small trial 
designs for NASH patients and leaded to positive results demanding further research 
in the immediate future [104].  
4.0 Conclusions 
There is a documented global increase of NAFLD and NASH related to the 
epidemic of the metabolic syndrome and obesity leading to increasing morbidity, 
mortality and associated health costs. The research for better understanding the 
pathogenesis of NASH and determining new biomarkers of prognosis, disease 
progression and regression is of cardinal importance. This needs to take into account 
influence of genetics and the molecular mechanisms that are associated with the 
progression from NAFLD to NASH and which are not completely understood. Of the 
available therapeutic options, weigh loss of at least 10% results in resolution of 
NASH and fibrosis in the majority of patients within one year. No pharmacological 
treatment to date has produced such results. Pioglitazone and vitamin E are the only 
treatments that are recommended in the EASL and AASLD guidelines in selected 
cases, however both are associated with side effects and their long-term safety and 
efficacy are questionable. There is an increasing interest from the pharmaceutical 
industry in conducting studies in NASH, which will hopefully result in effective 
treatments in the years to come. 
5.0 Expert commentary 
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NAFLD is a slowly progressing disease and expected liver-related outcome take more 
than 25 years to occur. It is therefore unrealistic to expect the conduction of trials of 
such duration. The Federal Drug Agency (FDA) in the US has agreed to the use of a 
co-primary endpoint for trials in pre-cirrhotic NASH that consists of resolution of 
steatohepatitis without worsening of fibrosis or improvement in the fibrosis score 
without worsening of the steatohepatitis. This will grant approval through the 
accelerated access pathway, with the sponsor obligation to conduct a post-market trial 
to demonstrate that the improvement in these surrogate end-points translates into a 
clinical meaningful benefit to patients [105]. The presence or severity of NASH has 
not been associated with clinical outcomes in long-term cohort studies [106], whereas 
only the presence of advanced fibrosis was associated with liver-related events [107]. 
Moreover, there is significant intra- and inter-observer variability in the assessment of 
the NAS score, which has so far jeopardized the outcome of well-conducted RCTs 
[57, 93]. Therefore, the resolution of NASH endpoint (or any decrease of the NAS 
score) is of questionable utility. We propose the exploration of quantitative fibrosis 
assessment using the collagen proportionate area as a surrogate endpoint, that would 
allow for the detection of finer changes in fibrosis and could potentially shorten the 
duration of clinical trials [108, 109, 110]. CPA assessment would probably require a 
modified method to capture and measure the finer pericellular fibrosis which is 
present in NASH.  
Moreover, the identification of clinically relevant biomarkers of disease regression 
that could potentially alleviate the need for serial biopsies and would increase study 
recruitment is an unmet need. A current innovative medicines initiative call, which 
represents a collaboration between the European Commission and the European 
pharmaceutical industry, will hopefully address this issue.  
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Since NASH has multiple potential pathways of development, combination treatment 
will also be explored at some point in the future. Ultimately, if there are no large scale 
interventions from a public health policy perspective to actively implement changes in 
lifestyle, the toll of morbidity and mortality will continue to rise irrespective of any 
small scale success in pharmaceutical therapy. 
6.0 Five-year view 
At the moment, there are promising agents in large scale phase III trials (obeticholic 
acid, elafibranor) and others in phase II trials (cenicriviroc, simtuzumbab, volixibat) 
that target different pathways of NASH development and progression. As NASH is 
classified as a medical condition of an unmet therapeutic need, it has gained an 
accelerated access pathway for drug approval based on surrogate endpoints. It is 
therefore expected that within the next five years, there will be at least one approved 
agent for the pharmacological treatment of pre-cirrhotic NASH. It is also expected 
that biomarker research will have identified candidate markers that will allow better 
characterization of patients and reduce the need for a liver biopsy. 
7.0 Key issues  
* NAFLD has become the most common cause for chronic liver disease in the 
developed world.  
* Dietary and lifestyle interventions provide beneficial results but are difficult to 
maintain in the long term. 
* Although there is no universally approved medical treatment, both the EASL and 
AASLD guidelines suggest pioglitazone and vitamin E use in selected cases.  
* As NASH is classified as a medical condition of an unmet therapeutic need, it has 
gained an accelerated access pathway for drug approval based on surrogate endpoints. 
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* New agents as obeticholic acid and elafibranor have shown promising results in 
phase II and are currently in phase III trials.  
* Novel drugs aim at multiple targets and pathways, such as inflammation and 
oxidative stress, the gut liver axis, the metabolic factor and progression of fibrosis. 
* The exploration of surrogate outcomes with clinical relevance, such as quantitative 
fibrosis assessment using the collagen proportionate area, and biomarkers of disease 
progression and regression is important. 
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Table 1. Randomized controlled trials in patients with non-alcoholic 
steatohepatitis that included more than 50 patients and used liver histology as 
the primary outcome. 
A/a Author  Number of 
patients 
Intervention  Duration  Primary 
Outcome 
Result  
1 Ratziu V, 
2016 [93] 
276 patients Elafibranor 
2:1 
52 weeks Resolution of 
steatohepatitis 
without 
worsening of 
fibrosis 
Predefined end point not met  
2 Armstrong 
M.J, 2016 
[63] 
52 patients 
 
Liraglutide 
(1.8mg) 1:1 
48 weeks  Resolution of 
steatohepatitis 
without 
worsening of 
fibrosis 
Significant effect 
3 Neuschwa
nder-Tetri 
B, 2015 
(FLINT) 
[88] 
283 patients 
  
Obeticholic 
acid 
(25mg/d) 1:1 
72 weeks Improvement 
of NAS by at 
least 2 points, 
without 
worsening of 
fibrosis  
Significant effect 
4 Sanyal A, 
2014 [76] 
243 patients 
 
Ethyl-
Eicosapentan
oic Acid 
12 months Improvement 
of NAS, 
without 
No significant effect 
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(EPA-E)  2:1 worsening of 
fibrosis  
5 Wong 
VW, 2013 
[111]  
60 patients 
 
Phyllanthus 
urinaria 
(herb) 2:1 
24 weeks Change in 
NAFLD 
activity score  
No significant effect 
 
6 Torres D, 
2011 [47] 
137 patients 
 
Rosiglitazone 
vs 
Rosiglitazone 
& metformin 
vs 
rosiglitazone 
& losartan 
1:1:1 
12 months Improvement 
of steatosis, 
inflammationa
nd fibrosis 
No significant effect 
7 Lavine J, 
2011 
(TONIC) 
in children 
[46] 
173 patients  
 
Vitamin E vs. 
metformin 
vs. Placebo 
1:1:1 
96 weeks Sustained 
reduction in 
ALT 
No significant effect 
 
8 Malaguarn
era M, 
2010 [112] 
74 patients 
  
L-Carnitine 
supplementat
ion to diet 1:1  
24 weeks Liver 
biochemistry 
Significant improvement 
9 Sanyal A, 
2010 
(PIVENS) 
[57] 
247 patients 
 
Pioglitazone 
vs Vitamin E 
vs placebo 
1:1:1 
96 weeks Improvement 
in NAS score 
Vitamin E was superior to 
placebo, no benefit of 
pioglitazone over placebo 
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10 Leuschner 
U, 2010 
[78] 
185 patients Ursodeoxych
olic acid 1:1 
18 months An overall 
improvement 
of liver 
histology  
 
No significant effect 
11 Vilar 
Gomez E, 
2009 [113] 
60 patients Nutritional 
supplement 
Viusid  1:1 
6 months Improvement 
in NAS and  
fibrosis score 
Improvement in the NAS 
score but not in fibrosis 
12 Aithal 
G.P, 2008 
[56] 
74 patients Pioglitazone 
1:1 
12 months Reduction in 
hepatocyte 
injury and 
fibrosis  
Significant effect 
13 Ratziu V, 
2008 
(FLIRT) 
[49] 
63 patients Rosiglitazone   1 year Improvement 
of steatosis, 
necroinflamma
tion & fibrosis  
Normalization 
of 
transaminases  
 
Improved steatosis  
Normalized transaminase 
levels  
No improvement in fibrosis 
and NAS 
14 Lindor K, 
2004 [77] 
166 patients Ursodeoxych
olic acid 1:1 
2 years Histological 
and 
biochemical 
improvement 
No significant effect 
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Table 2. Ongoing clinical trials with new pharmacologic agents for patients with 
non-alcoholic steatohepatitis (clinical trials.gov accessed 20 Oct 2016). 
A/a ClinicalTrials.gov 
Identifier 
Phase Stage Agent Action  
1 NCT02704403 Phase III Recruiting Elafibranor 
(GFT505) 
dual PPARα/δ agonist 
2 NCT02654665 Phase III Recruiting Liraglutide & 
bariatric surgery 
GLP-1 analogue 
3 NCT02548351 Phase III Recruiting Obeticholic acid  FXR agonist  
4 NCT02541045 Phase III Recruiting Metadoxine Pyridoxine-pyrrolidone 
carboxylate 
5 NCT02605616 Phase II Recruiting A novel AZ agent  
6 NCT02913105 Phase II Not yet recruiting LMB763  
7 NCT02443116 Phase II Recruiting NGM282  Recombinant variant of 
FGF-19 (FGF-19 is a 
peptide hormone) 
8 NCT02279524 Phase IIb Recruiting Aramchol Conjugate of cholic and 
arachidic acid 
9 NCT02912260 Phase II Recruiting MGL-3196 small-molecule liver-
directed ß-selective THR 
agonist 
10 NCT02855164 Phase II Recruiting LJN452 FXR agonist 
11 NCT02854605 Phase II Not yet recruiting GS-9674 A synthetic non-steroidal 
FXR agonist 
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12 NCT02927314 Phase II Not yet recruiting CF102 A3 adenosine receptor 
agonist 
13 NCT02856555 Phase II Recruiting GS-0976 ACC inhibitor  
14 NCT02574325 Phase II Ongoing but not 
recruiting 
Niacin/ARI-
3037MO 
Vitamin B3 analog 
15 NCT02413372 Phase II Ongoing but not 
recruiting 
BMS-986036 Pegylated FGF-21 analogue 
(FGF-21 is a peptide 
hormone) 
16 NCT02217475 Phase II Ongoing but not 
recruiting 
Cenicriviroc dual CCR2/CCR5 
antagonist 
17 NCT02686762 Phase II Recruiting Emricasan  pan caspase inhibitor 
18 NCT02466516 Phase II Ongoing but not 
recruiting 
GS-4997 alone or 
with simtuzumab 
inhibitor of ASK1 
19 NCT02421094 Phase II Ongoing but not 
recruiting 
GR-MD-02 A complex carbohydrate 
drug that targets galectin-3 
20 NCT02316717 Phase II Recruiting IMM-124E is composed of anti-LPS 
antibodies and adjuvants, 
many of which are 
glycosphingolipids, 
targeting the gut 
microbiome and the innate 
immune system of the gut 
21 NCT02784444 Phase II Recruiting MSDC 0602K Insulin sensitizer  
22 NCT02442687 Phase II Recruiting JKB-121 Non-selective opioid 
antagonist  
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23 NCT01679197 Phase II Ongoing but not 
recruiting 
Metreleptin Recombinant human leptin 
24 NCT02681055 Phase II Recruiting MN-001/Tipelukast orally bio-available small 
molecule compound which 
demonstrates anti-
inflammatory activity 
25 NCT02510599 Phase II Recruiting CEM-
101/Solithromycin 
a new generation macrolide 
antibiotic 
26 NCT01919294 Phase II Recruiting Testosterone 
replacement  
 
27 NCT01672879 Phase II Ongoing but not 
recruiting 
GS-
6624/Simtuzumab  
Humanized anti-LOXL2 
monoclonal IgG4 antibody 
28 NCT01672866 Phase II Ongoing but not 
recruiting 
GS-
6624/Simtuzumab  
 
29 NCT02923154 Phase II Recruiting MT-3995 a selective aldosterone 
receptor antagonist 
30 NCT02612662 Phase I Recruiting AZD4076/RG-125 
(tetracosasodium)  
an anti-Mir directed against 
miR-103/107 
31 NCT02469272 Phase I Recruiting Fecal microbiota 
transplantation  
 
32 NCT02721264  Recruiting Fecal microbiota 
therapy  
 
33 NCT02196831  Recruiting Tesamorelin GHRH analogue 
PPAR, peroxisome proliferator-activated receptor; GLP, glucagon-like peptide; FXR, farnesoid X receptor; 
FGF, Fibroblast Growth Factor; THR, thyroid hormone receptor; ACC, Acetyl-CoA carboxylase; CCR, CC-
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chemokine receptor; ASK, apoptosis signal-regulating kinase; LPS, lipopolysaccharide; LOXL, lysyl oxidase-
like protein; GHRH, growth hormone-releasing hormone 
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